Table 1.
Feasible restrictions placed on attributes and levels for each mode of treatment
Attribute | Levels | Restrictions by mode of administration | ||||
---|---|---|---|---|---|---|
LA Oral | SC injection | IM injection | Implant | All modes | ||
Mode | LA Oral, SC Injection, IM Injection, Implant* | |||||
Frequency | 1, 4, 8, 12, 26, 52 weeks | 1 or 4 weeks | 1, 4, 8, or 12 weeks | 4, 8, or 12 weeks | 26 or 52 weeks | IF location = clinic or pharmacy, THEN dose frequency ≥ 4 |
Location | Home, pharmacy, clinic | Only home | Any | Not home | Only clinic | IF frequency = 1 week, THEN location = home |
Pain | None, mild, moderate | Only none | None or mild | Mild or moderate | Mild or moderate | |
Oral lead-in | 0, 3, 6 months | |||||
Negative reaction testing | Yes or no | |||||
Late dose leeway | Short, long* |
*Long-acting oral tablet, subcutaneous injection, intramuscular injection
*Short vs Long: For the late dose leeway attribute, the duration of time displayed to respondents for both the "short" and "long" levels was dependent on the dosing frequency of that alternative